针对EGFR外20插入突变在非小细胞肺癌中的向疗法
1Department of Medicine, Inha University College of Medicine, Incheon 22332, Republic of Korea.
International journal of molecular sciences
|June 19, 2024
概括
新的向疗法对非小细胞肺癌 (NSCLC) 具有EGFR外因子20插入,一种对传统治疗有抗性的突变,显示出前景. 像Amivantamab和Mobocertinib这样的药物提供了新的希望,尽管仍然存在挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 经常表现出表皮生长因子受体 (EGFR) 突变.
- EGFR外因子20插入代表了这些突变的一个子集 (1-10%),与对标准氨酸激酶抑制剂 (TKI) 的反应不佳有关.
研究的目的:
- 审查新兴的针对性治疗药物,用于携带EGFR外基子20插入的NSCLC.
- 评估新药的有效性和局限性,包括阿米万塔马布,莫博塞蒂尼布,波齐奥提尼布,齐帕尔蒂尼布和Sunvozertinib.
主要方法:
- 临床试验和针对EGFR外因子20插入NSCLC的向疗法研究的文献综述.
- 对药物的作用机制,临床疗效数据和耐药性模式的分析.
主要成果:
- 阿米万塔马布是一种双特异性抗体,显示出有效性,特别是在化疗时.
- 莫博塞蒂尼布,波齐奥提尼布,齐帕尔蒂尼布和Sunvozertinib作为TCI具有不同程度的前景,其中一些面临有效性限制或突变特异性反应.
- 抵抗和透中枢神经系统仍然是关键的挑战.
结论:
- 向性药物为用EGFR外基子20插入的NSCLC提供了改进的治疗选择.
- 需要进一步的研究来优化组合疗法,克服耐药性,并增强个性化治疗的诊断策略.
关键词:
在EGFR外20插入.我需要一个人来帮助我.莫博塞尔提尼布 (mobocertinib) 是一种药物.其他非小细胞肺癌.定丁尼的使用方法这就是sunvozertinib.铁氨基激酶抑制剂 铁氨基激酶抑制剂齐帕尔蒂尼布 (Zipalertinib) 是一种药物.更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K